RE: Past raises15 Apr 2026 10:23
Pharma research companies with no revenue, its arguably an entire lifestyle sector, and the riskiest in the whole market, they are all worth nothing without cash.
But That argument could have been used at every cash raise, the share price still offered an exit at higher than the prior raise.